Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13090648 | 1.00 | CTSS (0.42) | CTSSCYP3A4CTSBADRB3ADRA2B | |
| SCHEMBL3063879 | 1.00 | CTSS (0.42) | CTSSCYP3A4CTSBADRB3ADRA2B | |
| SCHEMBL13090656 | 0.92 | CTSS (0.39) | CTSSCYP3A4CTSBADRB3ADRA2B | |
| SCHEMBL15205087 | 0.92 | CTSS (0.39) | CTSSCYP3A4CTSBADRB3ADRA2B | |
| SCHEMBL15205088 | 0.92 | CTSS (0.39) | CTSSCYP3A4CTSBADRB3ADRA2B | |
| SCHEMBL15205396 | 0.91 | CTSS (0.41) | CTSSCYP3A4CTSBADRB3ADRA2B | |
| SCHEMBL13090655 | 0.91 | CTSS (0.41) | CTSSCYP3A4CTSBADRB3ADRA2B | |
| SCHEMBL3072347 | 0.90 | CTSS (0.39) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL3072349 | 0.90 | CTSS (0.39) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13090643 | 0.90 | CTSS (0.39) | CTSSCTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8377962-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CTSS 45/4885CYP3A4 353/4885CTSB 39/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CTSS 45/4885CYP3A4 353/4885CTSB 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.